Peking University-backed Yanchuang Capital co-led a series A round for Innoforce Pharmaceuticals that will support the construction of manufacturing facilities.
Innoforce Pharmaceuticals, a China-based biopharmaceutical firm, attracted $96m in a series A round co-led by Peking University-backed Yanchuang Capital on Monday, DealStreetAsia reported citing a WeChat post.
South China Venture Capital co-led the round, which also attracted existing backer Quan Capital.
Founded in 2018, Innoforce partners pharmaceutical firms for product development and operations management. Its aim is to drive the commercialisation of drugs in China, the US and Europe.
It runs a biotech innovation park and will…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
